Crossmark

Strategic and Statistical Considerations on the QT Assessment of Volasertib

Crossref DOI link: https://doi.org/10.1177/2168479017739826

Published Online: 2018-12-30

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wallenstein, Gudrun

Walter, Beate

Fritsch, Holger

Taube, Tillmann
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2018-07-01
More Information

Article History

Received: 21 March 2017

Accepted: 29 August 2017

First Online: 30 December 2018